MADRID, 13 May. (EUROPA PRESS) –
The shares of Atrys Health soared almost 10% on the stock market this Monday around 10:00 a.m., after publishing its results for the first quarter of the year on Friday, when it recorded a turnover of 51.4 million euros, a 6.0 million. 9% more.
Thus, the company opened the trading day with a rise of 9.9%, until exchanging its shares at a unit price of 3.44 euros, which led it to lead the increases in the continuous market together with Almirall.
Atrys also improved the adjusted gross operating result (Ebitda), with a growth of 17.2% compared to the same period in 2023, reaching 9.1 million euros.
In addition, all business segments grew during the first quarter of the year, with a special increase in the Diagnostics area, followed by the Oncology area and, finally, Prevention.
At the same time, the improvement in efficiency together with the containment of operating expenses (Opex) carried out in these first three months of the year translated into an increase of 1.6% in the Group’s adjusted Ebitda margin.
For its part, the gross margin registered a growth of 6.4% until March, reaching 34.9 million euros.
Atrys’ operating cash flow increased by 125% and adjusted operating cash flow from non-recurring expenses increased by 92% compared to the first three months of fiscal 2023, due to the growth experienced in Ebitda and the reduction in investment in capital expenditures (Capex).
Likewise, the company has successfully completed the issuance of contingent convertible bonds into shares, the so-called ‘CoCos’, for an amount of 11.7 million euros this week, with the same terms and conditions as the issuance executed last December by the company for an amount of 13.3 million euros.
By region, during the first quarter the company’s turnover in the Spanish market registered a growth of 5.2%, reaching 38.8 million euros.
In the Latin American market, the 13.9% growth in turnover stands out, reaching 9.36 million euros, driven by the good performance of the telediagnosis activity in Chile, Brazil and Colombia, as well as the activity of medical oncology in Mexico.
During the coming months, Atrys’ priority will be to “reinforce the organic growth of its ‘core business’ relying on the most innovative technologies,” explains Atrys’ general director, Isabel Lozano.
